Holiday Sale | Save 50%
SubscribeLogin
Holiday Sale | Save 50%
Published

Merck Secures Global Rights to Novel Cancer Drug in $3.3B Licensing Deal with LaNova

Summary by stocktitan.net
Merck expands oncology portfolio with exclusive rights to LM-299, a pioneering PD-1/VEGF bispecific antibody. Deal includes $588M upfront payment plus milestone opportunities.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

MerckMerck
RahwayRahway
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal